Skip to main content

16 August 2002

Deltec, the Minnesota-based infusion pump manufacturer, part of Smiths Group, Medical division, has received clearance from the Food and Drug Administration (FDA) to allow it to market its new insulin infusion pump in the treatment of diabetes.

The Deltec Cozmo insulin pump offers significant advantages over currently available pumps, most notably its ease of use and flexible programming. This allows people with diabetes to personalise their treatment to meet their lifestyle demands. It also has many safety features designed with paediatric use in mind. It is estimated that approx. six per cent of the U.S. population has diabetes.

The pump is a small, lightweight, mobile phone-size device worn by a person with diabetes to deliver insulin continuously, day and night, through a short, flexible plastic tube that is inserted just under the skin and changed every few days. Patient friendly features include a full-sized 300 unit insulin cartridge, power from a single AAA battery, and a large, easy-to-read display. These result from over 20 years of ambulatory pump development and manufacturing experience by Deltec.

"Deltec has a long history of developing high quality, reliable ambulatory infusion pumps," said Jim Stitt, president of Deltec. "We have combined that expertise with the needs identified from people with diabetes, certified diabetes educators, and physicians to develop a superior insulin pump."

Deltec has sold over 150,000 ambulatory infusion pumps worldwide, which are used in a variety of infusion therapies to deliver medications for chemotherapy, pain management, TPN, hydration and dialysis. They also deliver antibiotics and drugs to treat primary pulmonary hypertension, eliminate excess iron, prevent clotting and produce blood cells. The ambulatory nature of Deltec infusion pumps allows patients to maintain a better quality of life while undergoing their therapy.

Headquartered in St. Paul, Minnesota, Deltec is part of the Medical division of Smiths Group plc, and manufactures a wide range of infusion and access systems for domestic and international markets.

ENDS

Related articles

Diffraction (1)

Smiths Detection launches X-ray Diffraction technology to combat illegal narcotics and contraband trafficking  

Find out more Call to action arrow icon
Earth View

Smiths Group plc share buyback programme

Find out more Call to action arrow icon
Earth View

Half year results for 6 months ended 31 January 2024

Find out more Call to action arrow icon